F. Rolland

715 total citations
29 papers, 457 citations indexed

About

F. Rolland is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, F. Rolland has authored 29 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 8 papers in Otorhinolaryngology. Recurrent topics in F. Rolland's work include Cancer Treatment and Pharmacology (8 papers), Head and Neck Cancer Studies (8 papers) and Lung Cancer Treatments and Mutations (6 papers). F. Rolland is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Head and Neck Cancer Studies (8 papers) and Lung Cancer Treatments and Mutations (6 papers). F. Rolland collaborates with scholars based in France, Belgium and Switzerland. F. Rolland's co-authors include Thierry Conroy, G. Milano, Muriel Barberi‐Heyob, Jean‐Louis Merlin, A. Riviére, R. Féty, Agnès Hardouin, L. Campion, M C Etienne and G. Perrocheau and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

F. Rolland

28 papers receiving 446 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Rolland France	11	230	164	135	99	92	29	457
Ken Saijo Japan	12	232 1.0×	133 0.8×	68 0.5×	203 2.1×	92 1.0×	47	530
Ping Ai China	10	76 0.3×	74 0.5×	62 0.5×	70 0.7×	42 0.5×	39	263
Markus K. A. Herrmann Germany	14	224 1.0×	120 0.7×	48 0.4×	48 0.5×	174 1.9×	18	394
Pei‐Wei Huang Taiwan	10	175 0.8×	77 0.5×	36 0.3×	51 0.5×	49 0.5×	30	319
Xiongying Jiang China	13	124 0.5×	127 0.8×	35 0.3×	76 0.8×	111 1.2×	38	498
Kensaku Ito Japan	14	258 1.1×	311 1.9×	25 0.2×	84 0.8×	71 0.8×	35	499
Özden Altundağ Türkiye	12	158 0.7×	105 0.6×	76 0.6×	69 0.7×	146 1.6×	50	405
Francesca Arcadipane Italy	18	227 1.0×	234 1.4×	98 0.7×	26 0.3×	366 4.0×	47	618
Jeltje Schulten Germany	10	334 1.5×	222 1.4×	313 2.3×	117 1.2×	173 1.9×	14	603
Elias Tueni Belgium	11	355 1.5×	244 1.5×	167 1.2×	83 0.8×	143 1.6×	23	555

Countries citing papers authored by F. Rolland

Since Specialization

Citations

This map shows the geographic impact of F. Rolland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Rolland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Rolland more than expected).

Fields of papers citing papers by F. Rolland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Rolland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Rolland. The network helps show where F. Rolland may publish in the future.

Co-authorship network of co-authors of F. Rolland

This figure shows the co-authorship network connecting the top 25 collaborators of F. Rolland. A scholar is included among the top collaborators of F. Rolland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Rolland. F. Rolland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bourhis, Jean, Yungan Tao, Xiaonan Sun, et al.. (2021). LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. Annals of Oncology. 32. S1310–S1310. 49 indexed citations

Bourhis, Jean, C. Le Tourneau, Y. Pointreau, et al.. (2020). LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 31. S1168–S1168. 5 indexed citations

Oudard, Stéphane, Gero Kramer, Orazio Caffo, et al.. (2015). Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 115(5). 744–752. 4 indexed citations

Rolland, F., et al.. (2013). Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet’s syndrome: the concept of neutrophilic disease. International Journal of Dermatology. 52(10). 1185–1188. 15 indexed citations

Lhommé, C., Dominique Berton-Rigaud, Jean‐François Baurain, et al.. (2011). Results from a randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON).. Journal of Clinical Oncology. 29(15_suppl). 9116–9116. 3 indexed citations

Chevreau, Christine, Alain Ravaud, Bernard Escudier, et al.. (2011). Phase II trial of sunitinib in renal cell cancer with untreated brain metastases.. Journal of Clinical Oncology. 29(15_suppl). 4625–4625. 4 indexed citations

Oudard, Stéphane, I. Latorzeff, Philippe Beuzeboc, et al.. (2011). Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survival. Journal of Clinical Oncology. 29(15_suppl). 4523–4523. 2 indexed citations

Fizazi, Karim, F. Lesaunier, R. Delva, et al.. (2011). Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).. Journal of Clinical Oncology. 29(15_suppl). 4513–4513. 6 indexed citations

Oudard, Stéphane, I. Latorzeff, Philippe Beuzeboc, et al.. (2010). Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy ± docetaxel—An analysis of final safety results.. Journal of Clinical Oncology. 28(15_suppl). 4685–4685.

10.

Fizazi, Karim, R. Delva, Christine Chevreau, et al.. (2009). A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: Results of the GETUG S99 multicenter prospective study. Journal of Clinical Oncology. 27(15_suppl). 5031–5031. 2 indexed citations

11.

Postelmans, Laurence, Brigitte Pasteels, Laure Caspers, et al.. (2005). Photodynamic Therapy for Subfoveal Classic Choroidal Neovascularization Related to Punctate Inner Choroidopathy (PIC) or Presumed Ocular Histoplasmosis-Like Syndrome (POHS-Like). Ocular Immunology and Inflammation. 13(5). 361–366. 23 indexed citations

12.

Duffaud, Florence, Markus Borner, P. Chollet, et al.. (2004). Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. European Journal of Cancer. 40(18). 2748–2752. 30 indexed citations

13.

Bernier, J., M. van Glabbeke, C. Domenge, et al.. (2001). Results of EORTC phase III trial 22931 comparing, postoperatively, radiotherapy (RT) to concurrent chemo-radiotherapy (RT-CT) with high dose cisplatin in locally advanced head and neck (H&N) carcinomas (SCC). European Journal of Cancer. 37. S267–S267. 10 indexed citations

14.

Degardin, M., Joana Oliveira, L. Geoffrois, et al.. (1998). An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 9(10). 1103–1107. 21 indexed citations

15.

Féty, R., F. Rolland, Muriel Barberi‐Heyob, et al.. (1998). Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.. PubMed. 4(9). 2039–45. 96 indexed citations

16.

Fumoleau, P., et al.. (1997). Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. Oral Oncology. 33(5). 354–358. 9 indexed citations

17.

Caty, Armelle, Stéphane Oudard, Yves Humblet, et al.. (1997). Phase II study of vlnorelbine in patients with hormone refractory prostate cancer. European Journal of Cancer. 33. S33–S33. 5 indexed citations

18.

Boschi, Antonella, et al.. (1997). Malignant Bilateral Exophthalmos and Secondary Glaucoma in Iatrogenic Cushing's Syndrome. Ophthalmic surgery, lasers & imaging retina. 28(4). 318–320. 6 indexed citations

19.

Cappelaere, P, B Hecquet, F. Rolland, et al.. (1995). [Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].. PubMed. 82(9). 732–7. 3 indexed citations

20.

Féty, R., F. Rolland, Muriel Barberi‐Heyob, et al.. (1995). Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results.. PubMed. 14(6A). 2347–52. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact